Cargando…

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin

AIMS: The PDY6797 study evaluated efficacy, safety and pharmacodynamics of lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus (T2DM) insufficiently controlled with sulphonylureas with/without metformin. METHODS: This randomized, double-blind, placebo-controlled trial compr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seino, Y, Takami, A, Boka, G, Niemoeller, E, Raccah, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312941/ https://www.ncbi.nlm.nih.gov/pubmed/24524806 http://dx.doi.org/10.1111/dom.12276

Ejemplares similares

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
por: Fournier, Marie, et al.
Publicado: (2014)

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*
por: Seino, Y, et al.
Publicado: (2012)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
por: Barrientos‐Pérez, Margarita, et al.
Publicado: (2022)

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
por: Fonseca, Vivian A., et al.
Publicado: (2012)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
por: Rosenstock, Julio, et al.
Publicado: (2013)

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
por: Ratner, R E, et al.
Publicado: (2010)

Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
por: Shaefer, Charles F.
Publicado: (2016)

Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide
por: Pickford, Philip, et al.
Publicado: (2020)

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
por: van Dalem, Judith, et al.
Publicado: (2016)

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
por: Seino, Hiroaki, et al.
Publicado: (2016)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
por: Lim, Phei C., et al.
Publicado: (2015)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care
por: Orsini Federici, Marco, et al.
Publicado: (2021)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas’ Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus
por: Masilela, Charity, et al.
Publicado: (2021)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()
por: Van Gaal, Luc, et al.
Publicado: (2014)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
por: Kuwata, Hitoshi, et al.
Publicado: (2021)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis
por: Rayner, Christopher K., et al.
Publicado: (2020)

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
por: Aroda, Vanita R., et al.
Publicado: (2017)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis
por: Ahrén, Bo, et al.
Publicado: (2016)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

FRI651 Usage Of Modern Sulphonylureas And Metformin Fixed Dose Combination (fdc) In Type 2 Diabetes Mellitus (t2dm) Patients With Established Complications
por: M, Aushili, et al.
Publicado: (2023)

Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males
por: Okubo, Y, et al.
Publicado: (2011)

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies
por: Liu, Fuqiang, et al.
Publicado: (2021)

Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus
por: Huynh, Daniel J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5fjg4dif04ufcg6pgfhn4jik26